Will Sarepta Therapeutics Benefit From GlaxoSmithKline's Exit?

Glaxo's out of a drug partnership for a rare condition also targeted by a troubled drug from Sarepta. How will the exit impact Sarepta's future?

Jan 15, 2014 at 3:18PM

Sarepta Therapeutics (NASDAQ:SRPT) shares were up nearly 5% midday Monday after GlaxoSmithKline (NYSE:GSK) backed out of a competing drug for a rare condition with unmet needs. But does Glaxo's retreat indicate a market ripe for the picking-or signal further problems ahead for Sarepta's drug?  

GlaxoSmithKline returned full rights of Duchenne muscular dystrophy drug drisapersen to partner Prosensa (NASDAQ:RNA). Duchenne muscular dystrophy, or DMD, is a rare disorder that leads to muscle degeneration and an early death. No treatments for DMD currently exist on the market, which meant that drisapersen and Sarepta's eteplirsen were closely watched through their respective development pipelines. Unfortunately those pipelines had some clogs.

But will the setbacks continue for Sarepta? And can Prosensa's DMD projects succeed without GlaxoSmithKline?  

Why Glaxo stepped out 
Drisapersen failed a phase 3 trial last fall by missing a primary endpoint measuring how far patients can walk over the course of six minutes. The distance improvement over the course of 48 weeks wasn't significantly better than placebo. 

Sarepta shares spiked on drisapersen's setback because eteplirsen looked set for an accelerated approval and a straight shot to market monopoly. But Sarepta received its own bad news the following month when the Food and Drug Administration advised against filing for the accelerated approval and Sarepta's shares tumbled nearly 60% on the news. 

But while eteplirsen was knocked back a peg, it's too soon to count the drug out of contention. 

Will eteplirsen make it to approval? 
Eteplirsen reported positive phase 2b results met the six-minute walk endpoint and an additional endpoint that measured levels of dystrophin-a muscle fiber protein normally decreasing in DMD patients. The drug achieved statistically significant results on both  measures, but the trial was quite small with only 12 patients, which made it unlikely that the FDA would allow for an accelerated approval.

But then the phase 3 failure of drisapersen complicated matters. The FDA said that Glaxo-Prosensa's failure cast "considerable doubt" on Sarepta's mid-stage data. That's because the failed trial showed that the dystrophin biomarker used might not actually indicate a clinical benefit. And the FDA also questioned whether the six-minute walk results were as significant as it seemed.  

So eteplirsen now heads into late-stage trials early this year. And it's those results that will ultimately decide eteplirsen's fate. Sarepta investors hope for further data proving eteplirsen's potential. But the fear is that eteplirsen will follow drisapersen's path of positive mid-stage data followed with a late-stage failure.

Is Prosensa out of contention? 
This week's announcement marks the end of the DMD partnership Prosensa and Glaxo formed in 2009. Glaxo had the exclusive worldwide license for drisapersen's development and commercialization plus the options on three more DMD pipeline projects . Prosensa received $25 million upfront and was eligible for milestone payments of up to $655 million if all four DMD drugs proved successful. The company also had participatory rights and the choice to expand its commercial rights in Europe. 

Glaxo has now walked away from the entire partnership. Prosensa has regained or retained rights to all four DMD drugs in its pipeline.  Prosensa hasn't specified its next step but the company has to stick with its DMD pipeline considering those are the only drugs that have made it past the preclinical stage. And the entire pipeline is finished off with two additional drugs for Huntington's disease and myotonic dystrophy. 

But Prosensa will have trouble making it to market without Glaxo's monetary backing. And the company's sole late-stage candidate is essentially dead in the water. Time will tell if one of the early stage DMD drugs shows any promise but Sarepta will have an outcome long before Prosensa could come back as a strong contender. 

Foolish final thoughts 
GlaxoSmithKline didn't have much of an investment in DMD, but the company's drop-out further weakens Prosensa's near-term prospects. Sarepta and Prosensa are both overly dependent on their respective drugs receiving approval. Sarepta looks to have a better shot at this stage of the game but it's the late-stage data that will make or break the drug.

Game-changing biotech stocks to watch
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Brandy Betz has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers